Saturday - May 16, 2026
Perioperative Imfinzi Plus Neoadjuvant EV Showed Statistically Significant and Clinically Meaningful Improvements in Event-Free Survival and Overall Survival in Muscle-Invasive Bladder Cancer in the Phase III VOLGA Trial
May 15, 2026
WILMINGTON, Delaware, May 15 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Perioperative IMFINZI(R) (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial

Perioperative IMFINZI plus IMJUDO(R) (tremelimumab-actl) and neoadjuvant EV showed a statistically significan . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products